Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): long-term results of a phase II study (Q77737363)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

title

Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): long-term results of a phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference

B Jeremic

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Y Shibamoto

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

B Milicic

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

N Nikolic

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

A Dagovic

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

S Milisavljevic

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

language of work or name

English

0 references

publication date

1 December 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Radiation Oncology Biology Physics

7 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

page(s)

1091-1096

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

Improved survival of patients with unresectable non-small-cell bronchogenic carcinoma by an innovated high-doseEn-Bloc radiotherapeutic approach

7 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Report by the radiation therapy oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Radiotherapy in the management of locally advanced lung cancer of all cell types: final report of randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Signiicant Effect of Adjuvant Chemotherapy on Survival in Locally Advanced Non-Small-Cell Lung Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

The interaction of cisplatin plus etoposide with radiation +/- hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Results of combination chemotherapy and thoracic radiation therapy for unresectable non-small cell carcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Concurrent daily carboplatin and accelerated hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

Dose escalation for non-small cell lung cancer using conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900283-1

7 January 2021

10.1016/S0360-3016(98)00283-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9869234%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference